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Abstract 
 Pharmaceutical companies continue to seek innovative ways to explore whether a drug 
under development is likely to be suitable for all or only an identifiable stratum of patients in the 
target population.  The sooner this can be done during the clinical development process, the better 
it is for the company, and downstream for prescribers, payers, and most importantly, for 
patients.  To help enable this vision of stratified medicine, we describe a powerful statistical 
framework, Patient Response Identifiers for Stratified Medicine (PRISM), for the discovery of 
potential predictors of drug response and associated subgroups using machine learning 
tools. PRISM is highly flexible and can have many “configurations”, allowing the incorporation 
of complementary models or tools for a variety of outcomes and settings. One promising PRISM 
configuration is to use the observed outcomes for subgroup identification, while using 
counterfactual within-patient predicted treatment differences for subgroup-specific treatment 
estimates and associated interpretation. This separates the “subgroup-identification” from the 
“decision-making” and, to facilitate clinical design planning, is a simple way to obtain unbiased 
treatment effect sizes in the discovered subgroups. Simulation results, along with data from a real 
clinical trial are used to illustrate the utility of the proposed PRISM framework. 
1 Introduction 
 Most medical treatments are designed and approved for the “average patient” in a one-size-
fits-all approach. The downside of this approach is that if the “average patient” within a broad 
population benefits from a study treatment, it is possible there are patients who receive no or 
limited benefit as well as patients who receive enhanced benefit. The overall goal of precision 
medicine, which focuses on the individual level, and stratified medicine, which focuses on finding 
interpretable subgroups, is to understand the underlying cause of disease, evaluate treatment 
response heterogeneity, and determine what types of patients respond or do not respond to a given 
treatment1. While this can be assessed post-hoc if the drug is shown to be beneficial, on average, 
in the overall population, this approach misses the opportunity to leverage information on 
treatment response heterogeneity for improving both subsequent trial design and other decision 
making. Further, along with recent advances in technology and data availability, rapid 
identification of subgroups has the potential to improve patient care and accelerate drug 
development2. 
 The focus on this work is more aligned with stratified medicine, where we aim to identify 
subgroups of patients based on treatment response heterogeneity. For example, consider a Phase 
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II study where an experimental drug is compared to a control. Suppose the strategy is to test for 
efficacy only in the overall population and, if successful, a confirmatory Phase III trial is initiated. 
Three potential scenarios could occur: (1) The drug is truly efficacious for all patients and this 
strategy will be successful no matter what, (2) The drug proves efficacious overall, but the 
treatment effect is diluted by patients who receive none or limited benefit, or (3) The drug is not 
efficacious overall but certain patients do receive clinically relevant benefit.  Although all patients 
benefit in Scenario (1), knowledge of treatment response heterogeneity can improve design 
planning and analysis of the subsequent Phase III trial. In Scenario (2), understanding that some 
patients do not respond to the treatment can also improve the trial design. For example, suppose 
that patients with a certain genotype seem to benefit but those without do not. Genotype could then 
be a stratification factor in Phase III. Alternatively, if there is strong enough evidence, such as 
biological rationale or other supporting information, the Phase III study could focus on patients 
with the given genotype. In Scenario (3) where the drug is not efficacious overall, the decision 
may be to abandon the drug altogether even though there may be patients that truly benefit from 
the study drug. In any these scenarios, drug development is improved by understanding both the 
overall treatment effect along with subgroup specific treatment effects.   
 Overall, there are four broad frameworks for subgroup identification: global outcome 
modeling, global treatment effect modeling, optimal treatment regimes, and local modeling3. 
Global outcome modeling fits a model (or treatment specific models) that aims to capture 
treatment-by-covariate interactions. The resulting predictions can then be used to form subgroups. 
Here, ensemble models and penalized regression are commonly employed such as the non-
parametric Virtual Twins and FindIT methods4,5. Global treatment effect modeling aims to 
partition the covariate space by directly targeting the treatment interactions. For example, the 
interaction tree method extends the classic CART method6 by including a treatment-by-split 
interaction and thus searches for partitions related to treatment response heterogeneity7-9. Other 
tree-based methods include GUIDE10 and model-based partitioning (MOB)11-13. Both allow for the 
flexibility to look for partitions corresponding to prognostic covariates (associated with the 
outcome irrespective of the treatment assignment), predictive covariates (associated with the 
outcome conditional on treatment), or both. In contrast to the previous frameworks, optimal 
treatment regimes focus on identifying the optimal treatment for each patient, rather than finding 
the best type of patients for each treatment. This approach often includes global outcome 
modeling14,15. Lastly, local modeling searches for regions of the covariate space with improved 
treatment effects3. This avoids needing to estimate an outcome function over the entire covariate 
space and instead focuses in on specific covariate space regions. Examples include SIDES, 
SIDESCREEN, and PRIM16-18. Lastly, it is worth mentioning the Bayesian Credible Subgroup 
methodology19. Here, the idea is to find covariate regions where all members simultaneously have 
a treatment effect exceed some pre-specified threshold.  
 Our proposed method, PRISM (Patient Response Identifiers for Stratified Medicine), is a 
general-purpose subgroup identification approach that can incorporate a wide variety of machine 
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learning tools and subgroup identification models. As noted above, there are many approaches to 
subgroup identification and a key motivation for PRISM was to consolidate these various 
approaches into a unified framework. This facilitates the construction of PRISM “configurations” 
that can combine complementary methods or models. The key output is rule-based subgroups (if 
any) and, for both the overall and discovered subgroups, point-estimates and variability metrics 
(standard errors (SE), confidence intervals (CIs), probability statements) for decision making. 
Obtaining unbiased estimates is especially crucial for drug development since if a subgroup is 
identified and moved forward for further testing, biased estimated effect sizes may lead to incorrect 
estimates of the required sample size and thus compromise the power of any future study.  
In the next Section, we describe a motivating example involving a clinical trial from the 
anti-infectives domain. In-depth details of PRISM are provided in Section 3. The operating 
characteristics of PRISM are examined using a simulation study in Section 4 followed by a 
PRISM-based analysis of the motivating clinical trial data in Section 5. We conclude with a 
summary of results and a discussion of future directions.  
2 Clinical Trial Example: Clostridium Difficile Recurrence 
The data for our motivating example come from a phase III, double-blind, randomized, 
placebo-controlled clinical trial of an experimental drug (bezlotoxumab) in patients being treated 
for Clostridium Difficile (CDIFF)20 infection (CDI). CDIFF is the most common cause of 
infectious diarrhea in hospitalized patients and is estimated to cause nearly half a million cases in 
the US alone21. The infection is typically treated with antibiotics; despite the resulting “clinical 
cure” for most patients, many experience a recurrence of CDIFF infection within a relatively short 
time window.  The phase III trial was designed to assess whether bezlotoxumab, relative to 
placebo, reduces the risk of CDI recurrence, the latter defined as the development of a new episode 
of diarrhea (3 or more loose stools in 24 or fewer hours) and a positive local or central lab stool 
test for toxigenic CDIFF following clinical cure of the initial CDI episode. There were two 
bezlotoxumab containing arms; for illustration, both are combined into a single arm and referred 
to as the bezlotoxumab arm. Of interest here is the CDI recurrence risk difference between the 
bezlotoxumab and placebo arms with a clinically meaningful difference of -0.10, i.e., a 10 
percentage point lower CDI recurrence risk for bezlotoxumab versus placebo. Five baseline 
variables were pre-specified in the protocol as risk factors for CDI recurrence: prior history of CDI 
within past 6 months, immune compromised (Yes or No), CDI severity (Yes or No), prior history 
of CDI (ever, Yes or No), hypervirulent strain (Yes vs No) and age (<65 vs >=65).  An additional 
variable was subsequently identified in a genome-wide association study (GWAS): SNP+ (yes if 
patient had one or more copies of the minor allele for SNP rs251613, and no otherwise). All six 
variables will be used to illustrate the PRISM approach in the remainder of this article, and the 
analysis set is restricted to patients who had provided consent for the GWAS, resulting in sample 
sizes of 240 and 461 for placebo and bezlotoxumab, respectively. 
The forest plot in Figure 1 shows the observed CDI recurrence rates for each treatment and 
for the corresponding treatment difference separately for subgroups defined by the aforementioned 
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six variables.  Consistent with the original findings of the study, the presence of any of the 
following conditions resulted in an increased treatment effect: patients with Prior CDI (6 mon), 
immune compromised (yes), CDI severity (yes), SNP+, Age >=65, and Hypervirulent strain (yes). 
However, it isn’t exactly clear how to interpret these results. For example, what if patient had Prior 
CDI history but was age <65? What if a patient was SNP- but had prior CDI history? While the 
univariate forest plot is informative, interpretation is difficult and response to treatment is likely 
based on multiple baseline variables. This is where PRISM comes in. 
Figure 1: Forest Plot, CDIFF Example 
 
3 Methods 
The PRISM framework offers a roadmap for subgroup identification and subsequent 
decision making. PRISM consists of five steps which are summarized in Figure 2. The first step is 
to determine the question(s) or estimand(s) of interest. For example, what is the average treatment 
difference between the two treatments being compared? The second step filters out “noise” 
variables from a larger candidate set of baseline variables, with a goal of retaining variables that 
are plausibly related to the outcome for at least one treatment. The third step outputs “Patient-
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Level Estimates” (PLEs). PLEs are patient-level counterfactual quantities that relate to the 
question of interest. In our running example, this corresponds to the patient-level treatment effect, 
or the expected difference in response if the patient had received both treatments. Understanding 
patient-level treatment effects is a key aspect of both stratified and precision medicine. The fourth 
step determines rule-based interpretable subgroups. This can be based off the observed outcomes, 
the PLEs, or both. The final step involves parameter estimation and decision making both for the 
overall population and for the identified subgroups. To summarize, PRISM provides insight at the 
overall population level (is there a treatment effect, on average?) and at the patient or subgroup 
level (are there heterogeneous treatment effects?).  
PRISM can be implemented through the R package “StratifiedMedicine.” One novel 
feature of PRISM is that users can input their own methods or functions at each step of the 
algorithm. This flexibility allows for easy research-experimentation and timely incorporation of 
state-of-the-art modeling techniques. We now describe PRISM in detail.   
Figure 2: PRISM (Patient Response Identifiers for Stratified Medicine) 
 
  
Step 0: 
Estimand
•What is the question of interest?
•Let 𝜃𝜃0 correspond to the estimand(s) of interest in the overall population
•Data: (Outcomes, Treatment, Variables)= 𝒚𝒚,𝒂𝒂,𝒙𝒙
Step 1: 
filter
•Reduce covariate space / remove unnecessary covariates
f𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝒚𝒚,𝒂𝒂,𝒙𝒙 → 𝒚𝒚,𝒂𝒂,𝒙𝒙∗
Step 2:
ple
•Estimate counterfactuals or Patient-Level Estimates (PLE)
𝑝𝑝𝑖𝑖𝑖𝑖 𝒚𝒚,𝒂𝒂,𝒙𝒙∗ → �Θ 𝒙𝒙∗
Step 3:
submod
•Identify Distinct Subgroupss𝑢𝑢𝑢𝑢𝑚𝑚𝑜𝑜𝑜𝑜 𝒚𝒚,𝒂𝒂,𝒙𝒙∗, �Θ 𝒙𝒙∗ → 𝑆𝑆1 𝒙𝒙∗ , … , 𝑆𝑆𝐾𝐾 𝒙𝒙∗ = 𝑺𝑺(𝒙𝒙∗)
Step 4:
param
•Decision Making: Parameter estimation and inference (overall population and subgroup-specific)
𝑝𝑝𝑎𝑎𝑖𝑖𝑎𝑎𝑚𝑚 𝒚𝒚,𝒂𝒂,𝒙𝒙∗, �Θ 𝒙𝒙∗ ,𝑺𝑺(𝒙𝒙∗) → ?̂?𝜃𝑘𝑘,𝑆𝑆𝑆𝑆 ?̂?𝜃𝑘𝑘 ,𝐶𝐶𝐶𝐶𝛼𝛼 ?̂?𝜃𝑘𝑘 ,𝑃𝑃(?̂?𝜃𝑘𝑘 > 𝑐𝑐) 𝑓𝑓𝑜𝑜𝑖𝑖 𝑘𝑘 = 0, …𝐾𝐾
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For 𝑖𝑖 = 1, … , 𝑛𝑛 patients, let (𝒀𝒀𝑖𝑖,𝐴𝐴𝑖𝑖 ,𝑿𝑿𝑖𝑖) represent the patient level random variable data 
structure where 𝒀𝒀𝑖𝑖 is J-dimensional vector of patient outcomes (binary, continuous, ordinal, time-
to-event, etc), 𝐴𝐴𝑖𝑖 is a treatment variable, and 𝑿𝑿𝑖𝑖 = (𝑋𝑋𝑖𝑖1, … ,𝑋𝑋𝑖𝑖𝑖𝑖)𝑇𝑇is a p-dimensional covariate 
vector. The vector of outcomes 𝒀𝒀𝑖𝑖 could be a vector of longitudinal measurements, a combination 
of safety and efficacy outcomes (benefit-risk), or a single efficacy measure. The treatment variable 
could correspond to a binary treatment variable where 1 corresponds to the test/experimental drug 
and 0 corresponds to the control, or perhaps multiple treatments or dose levels. The observed 
values of the random variables are denoted as (𝒚𝒚𝑖𝑖,𝑎𝑎𝑖𝑖,𝒙𝒙𝑖𝑖). Lastly, define the observed “stacked” 
data as (𝒚𝒚,𝒂𝒂, 𝒙𝒙) where y is a n by j matrix, a is a n-length vector, and x is a n by p matrix. Next, 
each step of PRISM in described in detail. For context, the running example is a randomized 
control trial (RCT) where patients are randomized 1:1 to either the test drug or the control and the 
outcome of interest is continuous (e.g., tumor size change) or binary (e.g., CDI recurrence). 
Step 0: Estimand 
 The first step is to determine the estimand(s) or question of interest(s). Let 𝜃𝜃0 correspond 
to the estimand(s) of interest in the overall population with corresponding estimate 𝜃𝜃�0. For ease of 
notation, 𝜃𝜃0 could refer to multiple estimands or a single estimand. For example, for a continuous 
efficacy outcome and binary treatment, the estimand of interest is often the average treatment 
effect (ATE), 𝜃𝜃0 = 𝑆𝑆(𝑌𝑌|𝐴𝐴 = 1) − 𝑆𝑆(𝑌𝑌|𝐴𝐴 = 0). The ATE estimate, 𝜃𝜃�0 = 𝑆𝑆�(𝑌𝑌|𝐴𝐴 = 1) −
𝑆𝑆�(𝑌𝑌|𝐴𝐴 = 0), could then be obtained through ordinary least squares (OLS) adjusted for some 
number of prognostic and/or predictive covariates. Alternatively, there may be multiple estimands 
of interest: 
𝜃𝜃0 = [𝑆𝑆(𝑌𝑌|𝐴𝐴 = 0),𝑆𝑆(𝑌𝑌|𝐴𝐴 = 1),𝑆𝑆(𝑌𝑌|𝐴𝐴 = 1) −  𝑆𝑆(𝑌𝑌|𝐴𝐴 = 0)]. 
Step 1: Filter 
The second step is to filter variables that are deemed unrelated to the outcomes for either 
treatment. While there are trade-offs for any filtering approach, removing “noise” variables that 
are completely unrelated to the outcomes and/or treatments will enhance the performance of any 
subgroup identification method. Formally: 
𝑓𝑓𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖(𝒚𝒚,𝒂𝒂,𝒙𝒙)  →  (𝒚𝒚,𝒂𝒂,𝒙𝒙∗)  
where 𝑓𝑓𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖(. ) is some model based on the observed data and outputs a potentially smaller 
covariate space 𝒙𝒙∗ with dimension 𝑛𝑛 × 𝑞𝑞 where 𝑞𝑞 ≤ 𝑝𝑝. Examples of filtering tools include 
univariate p-values, elastic net22, and random forest variable importance with confidence 
intervals23.  
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Step 2: Patient-Level Estimate (PLE) 
Define the PLE model as: 
𝑝𝑝𝑖𝑖𝑖𝑖(𝒚𝒚,𝒂𝒂,𝒙𝒙∗)  → � Θ�(𝒙𝒙∗1), … ,Θ�(𝒙𝒙∗𝑖𝑖), … ,Θ�(𝒙𝒙∗𝑛𝑛)� =  Θ�(𝒙𝒙∗) 
where 𝑝𝑝𝑖𝑖𝑖𝑖(. ) is some model based on the observed data which outputs a matrix of PLEs where 
Θ�(𝒙𝒙∗𝑖𝑖) contains the patient-level estimates of 𝜃𝜃0. For the continuous outcome and binary 
treatment example, the PLE is often referred to as the estimated individual treatment effect 
(ITE). Let 𝜇𝜇(𝑎𝑎,𝒙𝒙∗) = 𝑆𝑆(𝑌𝑌|𝐴𝐴 = 𝑎𝑎,𝑿𝑿∗ = 𝒙𝒙∗) denote the outcome regression model with estimates 
?̂?𝜇(𝑎𝑎,𝒙𝒙∗). Then: 
Θ�(𝒙𝒙∗𝑖𝑖) = ?̂?𝜇(𝑎𝑎 = 1, 𝒙𝒙∗𝑖𝑖) − ?̂?𝜇(𝑎𝑎 = 1, 𝒙𝒙∗𝑖𝑖) 
PLEs are informative of the underlying patient heterogeneity and subgroups can be directly 
identified by partitioning the PLEs. For the continuous outcome example, note that ?̂?𝜇(𝑎𝑎,𝒙𝒙∗𝑖𝑖) 
corresponds to the estimated expected response as a function of the vector 𝑿𝑿∗𝑖𝑖 and treatment 
assignment 𝐴𝐴𝑖𝑖 evaluated at 𝒙𝒙∗𝑖𝑖 and a. In parallel arm trials, patients do not receive both treatments 
and PLEs must be estimated from the data. For the continuous outcome example, possible PLE 
models include linear models with explicit treatment by covariate interactions (e.g., 𝑌𝑌~𝛽𝛽𝑋𝑋 + 𝛼𝛼𝐴𝐴 +
𝛾𝛾𝑋𝑋𝐴𝐴), fitting random forest models for each treatment group separately4,24, the related causal forest 
method25, and BART26.  
Step 3: Subgroup Identification (submod) 
The next step is to find rule-based and interpretable subgroups. Define the subgroup model 
as: 
𝑠𝑠𝑢𝑢𝑢𝑢𝑚𝑚𝑜𝑜𝑜𝑜 �𝒚𝒚,𝒂𝒂, 𝒙𝒙∗,Θ�(𝒙𝒙∗)� →  {𝑆𝑆1(𝒙𝒙∗), … , 𝑆𝑆𝐾𝐾(𝒙𝒙∗)} = 𝑺𝑺(𝒙𝒙∗)  
where 𝑠𝑠𝑢𝑢𝑢𝑢𝑚𝑚𝑜𝑜𝑜𝑜(. ) maps the observed data and/or PLEs to 𝑘𝑘 = 1, … ,𝐾𝐾 distinct subgroups and 
𝑆𝑆𝑘𝑘(𝒙𝒙∗) defines some mapping of the covariate space for subgroup k. Subgroups can be defined by 
one binary variable,  {𝑆𝑆1(𝒙𝒙∗): [𝑋𝑋1 = 0], 𝑆𝑆2(𝒙𝒙∗): [𝑋𝑋1 = 1] }, as well as by multiple variables, for 
example  �𝑆𝑆1(𝒙𝒙∗): [𝑋𝑋𝑙𝑙 < 𝑐𝑐, 𝑋𝑋𝑗𝑗 = 1], 𝑆𝑆2(𝒙𝒙∗): [𝑋𝑋𝑙𝑙 ≥ 𝑐𝑐,𝑋𝑋𝑗𝑗 = 1], 𝑆𝑆3(𝒙𝒙∗): [𝑋𝑋𝑗𝑗  = 0] �  where 
subgroups are defined by 𝑋𝑋𝑗𝑗 = 0 and within 𝑋𝑋𝑗𝑗=1 by some cutoff c for continuous variable 𝑋𝑋𝑙𝑙. 
Examples of subgroup models include VirtualTwins4, CART6, CTREE11, MOB12, SIDES16, 
interaction trees8, and GUIDE27.  
Step 4: Decision Making (param) 
The final step is parameter estimation and inference within the discovered subgroups and 
the overall population. Importantly, the point estimates in the overall and subgroup-specific 
populations should be unbiased, i.e. 𝑆𝑆�𝜃𝜃�𝑘𝑘� = 𝜃𝜃𝑘𝑘 and 𝑆𝑆�𝜃𝜃�0� = 𝜃𝜃0. The standard error of the 
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estimate 𝑆𝑆𝑆𝑆(𝜃𝜃𝑘𝑘�), confidence intervals with nominal level 1 − 𝛼𝛼, 𝐶𝐶𝐶𝐶𝛼𝛼(𝜃𝜃�𝑘𝑘), and probability 
statements, for example 𝑃𝑃(𝜃𝜃�𝑘𝑘 > 𝑐𝑐) where 𝑐𝑐 is some threshold, are also needed for decision 
making. Define the parameter model as: 
𝑝𝑝𝑎𝑎𝑖𝑖𝑎𝑎𝑚𝑚�𝒚𝒚,𝒂𝒂,𝒙𝒙∗,𝜽𝜽�(𝒙𝒙∗),𝑺𝑺(𝒙𝒙∗) � →  �𝜃𝜃�𝑘𝑘 , 𝑆𝑆𝑆𝑆�𝜃𝜃�𝑘𝑘�,𝐶𝐶𝐶𝐶𝛼𝛼�𝜃𝜃�𝑘𝑘�,𝑃𝑃(𝜃𝜃�𝑘𝑘 > 𝑐𝑐) � 𝑓𝑓𝑜𝑜𝑖𝑖 𝑘𝑘 = 0,1, …𝐾𝐾  
where 𝑝𝑝𝑎𝑎𝑖𝑖𝑎𝑎𝑚𝑚(. ) is some function that outputs subgroup-specific, as well as in the overall 
population at 𝑘𝑘 = 0, point-estimates, SEs, CIs, and probability statements based on the identified 
subgroup rules and the observed data and/or PLEs. These metrics can also come directly from the 
subgroup model (Step 3). For the continuous outcome and binary treatment example, one approach 
is to fit separate linear regression models within each identified subgroup. Conceptually, this is 
what MOB does13. Lastly, in line with the multiple estimand setting (i.e. multiple treatment effects, 
or a survival curve), the 𝑝𝑝𝑎𝑎𝑖𝑖𝑎𝑎𝑚𝑚(. ) function could instead output multiple estimates for each 
discovered subgroup and the overall population.  
For the most part, subgroup-specific parameter estimation and subsequent inference using 
the observed data has two main problems: (1) 𝜃𝜃�𝑘𝑘 can be biased since the subgroup identification 
model and parameter model both use the same data, and (2) SEs, CIs, and probability statements 
ignore the inherent subgroup selection (as well as the estimation of the PLEs and filtering) and 
inference through these metrics is generally not valid. Non-parametric bootstrapping, which 
repeats PRISM Steps 1-4 across resamples of the data, is one general solution to these problems 
(Details in Appendix). Another semi-parametric/Bayesian approach, which doesn’t require 
resampling, is also discussed below. Both performed similarly in the simulations and real data 
example. 
3.1 Parameter Estimation: PLE 
The PLE approach obtains subgroup-specific point estimates by averaging the PLEs 
within each subgroup and in the overall population: 
𝜃𝜃�𝑘𝑘 =  1𝑛𝑛𝑘𝑘 � 𝜃𝜃�(𝒙𝒙∗𝑖𝑖)𝑛𝑛𝑘𝑘
𝑖𝑖∈𝑆𝑆𝑘𝑘
     (1) 
where 𝑛𝑛𝑘𝑘 is the sample size of subgroup k with 𝑛𝑛0 = 𝑛𝑛 (overall sample size) and 𝑖𝑖 ∈ 𝑆𝑆𝑘𝑘 
corresponds to the patients included in subgroup k for 𝑘𝑘 = 0,1, … ,𝐾𝐾. Next, define the patient 
specific “pseudo-outcomes” as: 
𝑦𝑦∗𝑖𝑖 =  �𝑎𝑎𝑖𝑖�𝑦𝑦𝑖𝑖 − ?̂?𝜇(𝑎𝑎 = 1, 𝒙𝒙∗𝑖𝑖)�𝜋𝜋�(𝒙𝒙∗𝑖𝑖) − (1 − 𝑎𝑎𝑖𝑖)�𝑦𝑦𝑖𝑖 − ?̂?𝜇(𝑎𝑎 = 0, 𝒙𝒙∗𝑖𝑖)�1 − 𝜋𝜋�(𝒙𝒙∗𝑖𝑖) �+ �?̂?𝜇(𝑎𝑎 = 1,𝒙𝒙∗𝑖𝑖) − ?̂?𝜇(𝑎𝑎 = 0,𝒙𝒙∗𝑖𝑖)� 
where 𝜋𝜋�(𝒙𝒙∗𝑖𝑖) = 𝑃𝑃�(𝑎𝑎 = 1|𝑿𝑿∗𝑖𝑖 = 𝒙𝒙∗𝑖𝑖) is the patient-level estimate of receiving treatment a=1. 
Note that this relates to the so-called “double robust” estimators28. The main difference is that we 
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only use the model fits (the second term above). Compared to only using the model fits for 
parameter estimation, taking the average of the pseudo-outcomes for parameter estimation results 
in higher bias when using MOB to find subgroups. This is because the pseudo-outcomes 
explicitly use the observed outcomes, which are also used to find the subgroups, for parameter 
estimation. Importantly, if the estimated probabilities or the estimated expectations are 
consistent, then:                       𝑆𝑆(𝑦𝑦∗𝑖𝑖)   = 𝑆𝑆(𝑌𝑌|𝐴𝐴𝑖𝑖 = 1,𝑿𝑿∗𝑖𝑖 = 𝒙𝒙∗𝑖𝑖) − 𝑆𝑆(𝑌𝑌|𝐴𝐴𝑖𝑖 = 0,𝑿𝑿∗𝑖𝑖 = 𝒙𝒙∗𝑖𝑖) 
𝑆𝑆 �𝑛𝑛𝑘𝑘
−1 � 𝑦𝑦∗𝑖𝑖
𝑛𝑛𝑘𝑘
𝑖𝑖∈𝑆𝑆𝑘𝑘
� =  𝑆𝑆�𝑌𝑌�𝐴𝐴𝑖𝑖 = 1,𝒙𝒙∗ ∈ 𝑆𝑆𝑘𝑘(𝒙𝒙∗)� − 𝑆𝑆�𝑌𝑌�𝐴𝐴𝑖𝑖 = 0, 𝒙𝒙∗ ∈ 𝑆𝑆𝑘𝑘(𝒙𝒙∗)� =  𝜃𝜃𝑘𝑘 
For a randomized clinical trial, the treatment assignment mechanism is known and 
𝑃𝑃�(𝑎𝑎 = 1|𝑿𝑿∗𝑖𝑖 = 𝒙𝒙∗𝑖𝑖) can be replaced with the marginal estimate 𝑃𝑃�(𝑎𝑎 = 1). The standard error 
𝑆𝑆𝑆𝑆(𝜃𝜃�𝑘𝑘) is then calculated as: 
𝑆𝑆𝑆𝑆�𝜃𝜃�𝑘𝑘  � =  �𝑛𝑛𝑘𝑘−2 ��𝑦𝑦∗𝑖𝑖 − 𝜃𝜃�𝑘𝑘  �2𝑛𝑛𝑘𝑘
𝑖𝑖∈𝑆𝑆𝑘𝑘
       (2) 
where 𝑆𝑆𝑆𝑆(𝜃𝜃�𝑘𝑘 )2 =  𝑉𝑉𝑎𝑎𝑖𝑖(𝜃𝜃�𝑘𝑘 ). CIs can then be formed using Z or t-intervals, for example, 
�𝜃𝜃�𝑘𝑘  ± 𝑖𝑖1−𝛼𝛼 2⁄ ,𝑛𝑛𝑘𝑘−1𝑆𝑆𝑆𝑆(𝜃𝜃�𝑘𝑘  )�.  
3.2 Parameter Estimation: Bayesian  
Based on our simulation studies and in line with intuitive expectations, the PLE parameter 
estimation approach yields relatively unbiased point-estimates with valid coverage. Based on 
these initial PLE parameter estimates (𝜃𝜃�𝑘𝑘), we propose a simple Bayesian approach to obtain a 
posterior distribution and thus calculate meaningful probability statements. For each identified 
subgroup, the posterior distribution of 𝑝𝑝�𝜃𝜃�𝑘𝑘�𝑜𝑜𝑎𝑎𝑖𝑖𝑎𝑎� is estimated by assuming a normal prior with 
mean 𝜃𝜃�0 and variance 𝛾𝛾 ∗ 𝑉𝑉𝑎𝑎𝑖𝑖(𝜃𝜃�0) where 𝛾𝛾 is some scaling factor. In this research, we set 𝛾𝛾 = 𝑛𝑛 
such that the prior is uninformative. Following standard normal theory: 
�𝜃𝜃�𝑘𝑘�𝑜𝑜𝑎𝑎𝑖𝑖𝑎𝑎�~𝑁𝑁 �𝜃𝜃�𝑘𝑘 ,𝑉𝑉𝑎𝑎𝑖𝑖�𝜃𝜃�𝑘𝑘��      (3) 
𝑉𝑉𝑎𝑎𝑖𝑖�𝜃𝜃�𝑘𝑘� =  �1 (𝛾𝛾 ∗ 𝑉𝑉𝑎𝑎𝑖𝑖(𝜃𝜃�0)⁄ ) + 1 𝑉𝑉𝑎𝑎𝑖𝑖�𝜃𝜃�𝑘𝑘�⁄ �−1    (4) 
𝜃𝜃�𝑘𝑘 =  𝑉𝑉𝑎𝑎𝑖𝑖�𝜃𝜃�𝑘𝑘� ∗ �𝜃𝜃�0/(𝛾𝛾 ∗ 𝑉𝑉𝑎𝑎𝑖𝑖(𝜃𝜃�0)) + 𝜃𝜃�𝑘𝑘 𝑉𝑉𝑎𝑎𝑖𝑖�𝜃𝜃�𝑘𝑘�� �     (5) 
Frequentist CIs can be estimated by taking the 𝛼𝛼 2⁄  and 1 − 𝛼𝛼 2⁄   quantiles of the posterior 
distribution. Similarly, probability statements are directly obtained from the posterior. Lastly, 
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while we assumed a normal posterior (with a normal prior), this could be easily be extended to 
different distributions (e.g., binomial).  
4 Simulation Study 
For this simulation study and the real data example, we describe three example PRISM 
configurations: PRISM(A), PRISM(B), and MOB. These are applicable to both the real data 
example and the simulations and details can be found in Table 1. MOB is a tree-based method 
that partitions the data based on prognostic and/or predictive variables. For the continuous 
outcome simulations, we use OLS-based MOB (lmtree); for the binary simulations and real-data 
example, since the main interest is the risk difference, we use GLM-based MOB (glmtree; 
binomial with identity link). OLS/GLM (binomial with identity link) models are then fit within 
each subgroup. PRISM(A) and PRISM(B) both include an elastic net filter, PLE through the 
“counterfactual forest” (random forest models), and parameter estimation with the PLEs or 
counterfactual estimates (with Bayesian update). For elastic net, the treatment variable is not 
included and thus focuses on finding prognostic variables. The key difference between 
PRISM(A) and PRISM(B) is the subgroup model: PRISM(A) identifies subgroups using the 
observed outcome and MOB, while PRISM(B) identifies subgroups using the counterfactual 
PLEs and CTREE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
Table 1: PRISM Configurations: Continuous or Binary Outcome with Binary Treatment 
PRISM Steps Configurations 
 
Methods 
MOB PRISM(A) PRISM(B) 
Filter Elastic Net (ENET) 
𝑆𝑆𝑁𝑁𝑆𝑆𝐸𝐸(𝒚𝒚,𝒙𝒙)  →  (𝒚𝒚,𝒂𝒂,𝒙𝒙∗) 
 
R package: glmnet (default settings, alpha=0.5) 
 
 Yes Yes 
PLE Counterfactual Forest (CF) 
𝑅𝑅𝑅𝑅1(1,𝒙𝒙∗) − 𝑅𝑅𝑅𝑅0(0,𝒙𝒙∗)  → 𝜽𝜽�(𝒙𝒙∗) 
 
Details: Fit RF models within each treatment group. 
R package: ranger (default regression forest, min.node.size=10% of 
total sample size) 
 
 Yes Yes 
Submod MOB 
𝑀𝑀𝑀𝑀𝑀𝑀(𝒚𝒚,𝑎𝑎,𝒙𝒙∗) →  𝑺𝑺(𝒙𝒙∗) 
R package: partykit 
Continuous Outcome: lmtree (Gaussian) 
Binary Outcome: glmtree (Binomial with identity link) 
 
Yes Yes  
CTREE 
𝐶𝐶𝐸𝐸𝑅𝑅𝑆𝑆𝑆𝑆(𝜽𝜽�(𝒙𝒙∗),𝒙𝒙∗) →  𝑺𝑺(𝒙𝒙∗) 
R package: partykit / ctree 
 
Details: For MOB/CTREE, default settings with alpha=0.10, 
max.depth=4, minimum node size set to 10% of total sample size. 
  Yes 
Param OLS/GLM: Fit 𝑦𝑦~𝑎𝑎 within each subgroup Yes   
PLE: Average PLEs within each subgroup. Apply 
Bayesian update and calculate Bayesian posterior. 
 Yes Yes 
 
The purpose of the simulation study was to evaluate the performance of PRISM with 
respect to (1) How often were subgroups formed based on the true predictive covariates, (2) 
Impact of filtering as more noise is added into the baseline covariate space, (3) Bias, relative 
efficiency, and coverage of the treatment effect estimates at the subgroup level, and (4) 
Compared to standard practice (i.e. treat all patients if overall treatment effect p-value<0.05), 
how effective is PRISM at assigning the “right” treatment to patients? 
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For all simulations, a sample size of N=800 was generated with a 1:1 randomization ratio 
for the test drug (A=1) and control (A=0).  The outcome was continuous (t-distribution) or 
binary (overall response rate of 30%) and there were, in truth, three covariates that were 
predictive (as well as prognostic) which defined subgroups with varying treatment effects. There 
were also 3 purely prognostic covariates that were correlated with the predictive covariates. In 
addition, there were either 6 or 56 noise variables. Two general subgroup scenarios were 
explored (1) Null setting where there is no treatment effect for any patient, and (2) Subgroup 
setting where there are in truth 4 subgroups. An “eight” subgroup scenario was also examined, 
but ultimately yielded similar results to the 4-subgroup scenario. In the Subgroup setting, while 
the overall treatment effect is non-zero (0.237 (continuous), 0.11 (binary)), 30% of the patients 
receive no benefit from the test drug versus the control. Subgroups were defined by a binary 
variable and two continuous variables. 1000 simulations were generated for each scenario. More 
details on the simulations can be found in the Appendix.  
4.1 Filtering and Subgroup Identification: Variable Selection 
These results focus on the Subgroup setting. See Figure 3. This plot shows the average 
percent correctly selected for predictive variables (3 in truth) and noise variables (6 or 56) that 
define the identified subgroups in PRISM(A)/PRISM(B) by filtering (No Filtering or ENET). As 
a reminder, PRISM(A) uses the observed outcomes and MOB while PRISM(B) uses the PLEs in 
CTREE for subgroup identification. Here we highlight key insights. In general, as expected, 
filtering improves the ability of each subgroup model to form subgroups based on the true 
predictive variables; this is especially true as more noise variables are added. For example, with 
6 noise variables and a continuous outcome, PRISM(A) selects ~80% of the true predictive with 
or without filtering, but with 56 noise variables, PRISM(A) with or without filtering selects 75% 
and 68% of the true predictive variables respectively. Compared to PRISM(B) (with or without 
filtering), PRISM(A) tends to select more of the true predictive variables and less of the true 
noise variables.  For example, with filtering in the Subgroup scenario with 56 noise variables and 
a binary outcome, PRISM(B) and PRISM(A) select 57% and 88% of the true predictive variables 
respectively and 5% (~3 noise variables) and 0.2% (<1 noise variables) of the true noise 
variables respectively. Lastly, while we don’t present results for prognostic variables, PRISM(A) 
tended to select ~20-30% of the purely prognostic variables and PRISM(B) tended to select ~10-
50% of the purely prognostic variables. In the Null setting, while there were no predictive 
variables, filtering also helped remove noise variables and select the true prognostic variables. 
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Figure 3: Filtering and Subgroup Models: Variable Selection 
 
Note: This plot illustrates the ability of different subgroup models, with and without filtering, to detect the true predictive/prognostic variables (in 
truth 3) and to ignore the noise variables (6 or 56). Key points: (1) Filtering improves the ability of any subgroup model and (2) Compared to 
PRISM(B) (subgroups based on counterfactual estimates using CTREE), PRISM(A) (subgroups based on observed outcomes using MOB) tends 
to select more of the truly predictive/prognostic variables and less of the noise variables.  
4.2 Bias, Relative, and Coverage 
As a benchmark, we include the “oracle” method which, for continuous outcomes, fits 
OLS models within each of the true subgroups, and for binary outcomes, estimates the risk 
difference within each of the true subgroups based on Miettinen-Nurminen method29. This 
represents an ideal situation where we know exactly how many and which subgroups there are. 
For the Null setting, this corresponds to fitting a single model in the overall population. For these 
simulations, results were similar with 6 or 56 noise variables and these settings were combined. 
See Figure 4 for bias, relative efficiency, and coverage results. Starting with overall bias, note 
that all methods have approximately zero average bias. In terms of absolute bias, which avoids 
cancelling out large positive and large negative bias with subgroups, PRISM(A) yields the lowest 
absolute bias. For relative efficiency, values < 1 correspond to MOB having superior efficiency. 
In the Null setting, the “oracle” method by far performs the best; mainly because the “oracle” 
knows there are no subgroups. PRISM(A), relative to MOB and PRISM(B), also shows 
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increased efficiency. In the Subgroup setting, PRISM(A) yields the highest efficiency. Lastly, for 
coverage, note that the dashed line corresponds to 93.6%, which is two standard errors (based on 
1000 simulations) below the desired 95% coverage. Both the “oracle” and PRISM(A) 
consistently maintain 95% coverage at the subgroup level. PRISM(B) yields valid coverage in 
most scenarios, but slightly below the simulation error bound in the Continuous-Null scenario. 
MOB, which uses OLS/GLM for parameter estimation, does not reach the desired 95% coverage 
in any of the scenarios. 
Figure 4: Bias, Relative Efficiency, and Coverage  
 
Note: This plot illustrates bias, relative efficiency, and coverage properties for three different subgroup methods and the “oracle” which knows 
the true subgroups. Panels correspond to different simulation scenarios based on outcome type (binary, continuous) and subgroups (Null, 
Subgroups). PRISM(A) has the lowest bias and compared to PRISM(B) and MOB, the highest efficiency, and valid coverage at the 95% level. 
The dashed line corresponds to 0.936, which is two standard errors (based on 1000 simulations) below the desired 95% coverage. 
4.3 Predicted Treatment Assignment 
Here, we evaluate how often patients are assigned the “right” treatment when there is in truth a 
non-zero treatment effect. In the subgroup simulation settings, 70% of patients should receive 
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treatment B while 30% of patients should receive treatment A. In the null treatment setting, all 
patients should receive treatment B. As a benchmark, we compare PRISM(A) to the “Standard” 
approach. For a continuous outcome, the “Standard” approach would be to fit a simple 
OLS/GLM model and if the p-value for the treatment effect is less than 0.05, the decision is to 
treat all patients with treatment B; otherwise treat all patients with treatment A. For this example, 
we use an “unadjusted model”; results were similar even when in an “ideal” adjusted analysis 
where we correctly knew the true predictive covariates,  𝑌𝑌~𝐴𝐴 + 𝑋𝑋1 + 𝑋𝑋2 + 𝑋𝑋3. For PRISM(A), 
patients are assigned to treatment B if their subgroup-specific posterior probability (See Section 
3.2) exceeds either 0.50 or 0.80; otherwise those patients are assigned to treatment A. See Figure 
5. 
Classification metrics of interest were accuracy (% of patients correctly assigned), positive 
predictive value (PPV; among the patients predicted to receive treatment B, what % should have 
received B?), and negative predictive value (NPV; among the patients predicted to receive A, 
what % should have received A?). Ideally, all three of these metrics should be high. Starting with 
the subgroup settings, we see that PRISM(A) yields the highest accuracy, PPV, and NPV. This is 
true for both 0.50 and 0.80 probability cutoffs. These different probability cutoffs illustrate a 
general trade-off: lower cutoffs increase NPV while higher cutoffs increase PPV.  Lastly, in line 
with intuition since PRISM(A) uses MOB to find subgroups, using only MOB (with OLS/GLM 
parameter estimation and Bayesian probabilities) yielded similar classification metrics. 
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Figure 5: Predicted Treatment Assignment, PRISM(A) vs Standard Practice 
 
Note: This plot illustrates classification metrics for PRISM(A) and “Standard Practice”. Standard Practice fits a single treatment-adjusted OLS or 
GLM model and if the p-value<0.05, all patients will receive treatment “B”. Otherwise, patients receive treatment “A”. Overall, PRISM(A) yields 
higher accuracy, higher positive predictive value (ppv), and higher negative predictive value (npv).  
4.4 Summary of Simulation Results 
 Overall, these results indicate that (1) Filtering improves the performance of subgroup 
identification, (2) PRISM(A) tends to select the true predictive variables more often than 
PRISM(B), (3) PRISM(A) yields the lowest bias, highest relative efficiency, and valid coverage, 
(4) Compared to “Standard Practice” (treat everyone or not), PRISM(A) yields higher accuracy, 
PPV, and NPV with regards to assigning the “right” treatment assignment. The final point is 
especially important as the overall goal of stratified medicine is to assign the “right” treatment to 
the “right” patient. The first three properties directly relate to the success of treatment 
assignment, and furthermore, are important since subgroups should ideally be based on the true 
predictive factors and for any identified subgroup, decision making requires relatively unbiased 
treatment effect estimates and an understanding of the variability. Lastly, we point out that while 
in the simulations treatment assignments in PRISM(A) were based on select posterior probability 
thresholds, similar results can be obtained through using CIs. Depending on the threshold 
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(probability threshold, CI alpha level), there is of course a trade-off between classification 
metrics that must be considered.  
5 Return to Clinical Trial Example 
Returning to the motivating clinical trial example, we present results using PRISM(A) (See 
Appendix for details); PRISM(B) and MOB yield similar conclusions. For the overall population 
the estimated risk difference [95% CI] was   -0.10 [-0.17, -0.03]. After filtering, all variables 
remained except for CDI severity. See Figure 6 for the main results through a PRISM tree plot. In 
total, there were four identified subgroups defined by SNP+, prior CDI history, and age. In each 
terminal node (nodes 3,4,6,7) or identified subgroup, we present the estimated CDI recurrence (%) 
for placebo and bezlotoxumab, the estimated risk difference (Diff(B-P) [95% CI]), Bayesian 
probability statements, and the posterior distribution of the estimated risk difference. First, for 
patients who are SNP- (SNP+ = No), the results vary by prior CDI history (no history, -0.01 [-
0.12, 0.10]; history, (-0.11 [-0.30, 0.07]).  For SNP+ patients, the results vary by CDI history and 
age group (Prior CDI, -0.21 [-0.41, -0.01]; No Prior CDI, age>=65, -0.25 [-0.44, -0.07]; age<65, -
0.12 [-0.23, -0.00]). The probability statements are also informative. With the exception of SNP- 
patients with no prior CDI history, Prob(Diff(B-P)<0) was greater or equal to 89%, suggesting that 
these subgroups have some benefit from using bezlotoxumab versus placebo. On the other hand, 
Prob(Diff(B-P)<-0.10) is the estimated probability that a subgroup has an estimated treatment 
effect beyond the clinically meaningful threshold. In the worst performing subgroup (SNP- with 
no prior CDI history), Prob(Diff(B-P)<-0.10)=0.05, suggesting that this group (~41% of the 
population) has limited benefit from using bezlotoxumab. In contrast, Prob(Diff(B-P)<-0.10) was 
0.86 and 0.95 respectively for the best performing subgroups (SNP+, Prior CDI; SNP+, No Prior 
CDI, age>=65).  
Overall, these results indicate that patients with no prior CDI history and SNP- status had 
limited reduction in CDI recurrence from using bezlotoxumab, while patients with prior CDI 
history or a SNP+ status had a clinically significant reduction in CDI recurrence. In general, the 
benefiting groups had high baseline risk of CDI recurrence, which is consistent with the regulatory 
label for bezlotoxumab. Lastly, if we combine the four benefitting groups (SNP+ or SNP- with 
prior CDI history), the estimated risk difference [95% CI] is -0.17 [-0.25, -0.08].  
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  Figure 6: PRISM Tree Plot, CDIFF Example 
 
Note: In each subgroup, we present the estimated CDI recurrence (%) for placebo/bezlotoxumab, the risk difference [95% CI], the probability 
that the estimated risk difference is less than the clinically meaningful threshold of -0.10 (obtained through Bayesian approach), and a density 
plot of the Bayesian posterior distribution (green shade to the left of -0.10; yellow for (-0.10,0); red for >0). Overall, patients who are SNP- with 
no prior history of CDI do not appear to benefit from bezlotuxumab. Patients who are SNP+ or have prior history of CDI show benefit. 
6 Discussion 
Overall, this paper has described a flexible and powerful subgroup identification 
framework, PRISM. PRISM is a five-step procedure with the over-arching goal of identifying 
subgroups and making decisions based on subgroup-specific treatment effects and variability 
metrics (CIs, SEs, probability statements). While PRISM is flexible with respect to the outcome 
type and number of treatments, this paper’s results focused on a binary treatment scenario (test 
drug vs control) and binary/continuous endpoints. Based on our simulation study, the best 
proposed method was PRISM(A), which uses the tree-based MOB to identify subgroups and 
counterfactual patient-level estimates (PLEs) for decision making. This yielded relatively 
unbiased subgroup-specific estimates and valid CIs which are crucial for decision making. In our 
real-data example, PRISM(A) revealed two distinct groups of patients, patients with no previous 
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CDI history and a SNP- status and patients with prior CDI history or a SNP+ status, with 
heterogeneous treatment effects.  
The goal of stratified medicine is to find subsets or subgroups of patients who are 
“similar” to each other in terms of treatment-specific responses. For drug development, the 
challenge is to identify subgroups in a “timely” fashion such that these insights can be used to 
better design clinical trials and target patients who likely benefit from the test drug. In earlier 
phases of drug development, due to the limited sample sizes, identifying subgroups or treatment 
response heterogeneity is more about informing the subsequent phases of drug development. For 
Phase II/III, if there is substantial evidence that there are subgroups of patients that respond to 
the test drug and groups of patients that do not respond the decision may be to seek approval for 
the responder group alone.  
The motivation of PRISM was to develop a general-purpose tool for the advancement of 
stratified medicine. Despite this, while advances in machine learning and development of more 
robust subgroup models will ultimately improve PRISM, having more patient-level data will 
have a larger impact. Real world data is one potential solution to expanding the data available for 
subgroup identification. For example, a recent study using electronic health data replicated 
associations between tumor mutation burden and response to immunotherapy in non-small lung 
cancer patients30. This illustrated the feasibility of utilizing a real-world data source with clinical 
and genomic factors for examining differential responses by patient characteristics. Pooling data 
across clinical trials with study drugs that have similar mechanisms of action, or multiple dose 
levels, may also help. Modern clinical designs such as the basket trial where the same treatment 
is studied in multiple indications31, could also be used to provide more patient-level data to at the 
very least, understand broad prognostic or risk factors. 
In summary, this manuscript developed and illustrated examples using a general-purpose 
subgroup identification framework, PRISM. Future extensions include a detailed look at survival 
data, multiple treatments or dose levels, bootstrap/resampling methods, benefit-risk, and 
development of more robust subgroup models. PRISM (with or without resampling) can also be 
directly implemented within the “StratifiedMedicine” R Package for continuous, binary, or 
survival data (experimental) and includes many features not directly discussed here. While there 
are many challenges, the end goal is to advance stratified medicine and determine whether there 
are subsets of patients who respond or do not respond to the test drug. Timely identification of 
subgroups has the potential to accelerate drug development by efficiently allocating resources to 
more-likely-to-respond patients, expand treatment options for prescribers, and most importantly, 
improve patient care. 
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Appendix 
Non-Parametric Bootstrapping 
Generate 𝑢𝑢 = 1, … ,𝑀𝑀 bootstrap resamples and for each resample b with data structure (𝒚𝒚𝒃𝒃,  𝒂𝒂𝒃𝒃,𝒙𝒙𝒃𝒃), run PRISM (Steps 1-4).  In each resample, there are 𝑘𝑘𝑏𝑏 = 1, … ,𝐾𝐾𝑏𝑏 bootstrap 
subgroups which likely differ from the original K subgroups, both in terms of the rules and the 
number of identified subgroups. Each bootstrap subgroup 𝑘𝑘𝑏𝑏 will also have an associated point-
estimate 𝜃𝜃�𝑘𝑘𝑏𝑏. The subgroup-specific estimate in resample b for subgroup k, which is identified 
using the observed data, is then calculated as: 
𝜃𝜃�𝑘𝑘,𝑏𝑏 =  � 𝑛𝑛(𝑘𝑘 ∩ 𝑘𝑘𝑏𝑏)𝜃𝜃�𝑘𝑘𝑏𝑏
𝑘𝑘𝑏𝑏
 � 𝑛𝑛(𝑘𝑘 ∩ 𝑘𝑘𝑏𝑏)
𝑘𝑘𝑏𝑏
�  
where 𝑛𝑛(𝑘𝑘 ∩ 𝑘𝑘𝑏𝑏) is the number of observations from the observed data that are in both the 
original subgroup k and the bootstrap subgroup 𝑘𝑘𝑏𝑏. Next, the smoothed or bagged bootstrap 
estimate is obtained by averaging the bootstrap estimates: 
𝜃𝜃�𝑘𝑘 =  1𝑀𝑀� 𝜃𝜃�𝑘𝑘,𝑏𝑏𝑏𝑏  
Bootstrap CIs for 𝜃𝜃�𝑘𝑘 are then calculated using the percentile method where the lower/upper 
limits correspond to the 𝛼𝛼 2⁄  and 1 − 𝛼𝛼 2⁄   quantiles of the bootstrap distribution for the 
subgroup-specific estimates, (𝜃𝜃�𝑘𝑘,1,… ,𝜃𝜃�𝑘𝑘,𝑏𝑏 , … ,𝜃𝜃�𝑘𝑘,𝐵𝐵). Probability statements can also be obtained 
using the subgroup specific bootstrap distributions. For example, with 𝐶𝐶(. ) denoting an indicator 
function: 
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𝑃𝑃�(𝜃𝜃𝑘𝑘 > 𝑐𝑐) =  1𝑀𝑀� 𝐶𝐶(𝜃𝜃�𝑘𝑘,𝑏𝑏 > 𝑐𝑐)𝑏𝑏  
Notably, the bootstrap smoothed estimate yielded similar properties as the PLE estimate (with or 
without the Bayesian update). The advantage of the bootstrap “smoothed” estimate is that it 
accounts for the uncertainty of the subgroup model. This approach however requires larger 
sample sizes. From our experience with both simulations and empirical data-sets, at smaller 
sample sizes (say N<200) it is more likely that at each bootstrap resample the subgroup model 
will find no subgroups, thus heavily shrinking the subgroup specific estimates towards the 
overall mean. 
Simulation Details 
For all simulations, a sample size of N=800 was generated with a 1:1 randomization ratio 
for the study drug (A=1) and standard of care (A=0). Covariates were generated from a 
multivariate normal distribution with mean zero and unit variances. In our simplest setting, there 
were 12 covariates total (𝑋𝑋1, … ,𝑋𝑋12) with three that were prognostic and predictive (𝑋𝑋1,𝑋𝑋2,𝑋𝑋3), 3 
covariates that were only prognostic (𝑋𝑋5,𝑋𝑋7,𝑋𝑋10), and 6 noise covariates 
(𝑋𝑋4,𝑋𝑋6,𝑋𝑋8,𝑋𝑋9,𝑋𝑋11,𝑋𝑋12). The pairwise correlations were set to 0.10 with the following exception: 
(𝑋𝑋1,  𝑋𝑋5), (𝑋𝑋2,  𝑋𝑋6), (𝑋𝑋3,  𝑋𝑋7) each had pairwise correlations of 0.30 (prognostics moderately 
correlated with predictive and prognostic covariates). Three of these continuous variables were 
then discretized into binary: 𝑋𝑋1=1 if 𝑋𝑋1>qnorm(0.80) else 0, 𝑋𝑋9=1 if 𝑋𝑋9>qnorm(0.70) else 0, and 
𝑋𝑋10=1 if 𝑋𝑋10>qnorm(0.40) else 0.  To further assess the impact of noise covariates, an additional 
50 continuous noise covariates were included in the multivariate normal distribution. These 
additional noise covariates had a pairwise correlation of 0.10 with all variables. The general 
point was to make subgroup identification difficult and in fact, we used a similar simulated data-
set for an internal subgroup data science contest.  
The outcome was continuous with a t-distribution (20 degrees of freedom) and a standard 
deviation of 0.85 or binomial. The mean of the outcome depended on the prognostic and/or 
predictive covariates (𝑋𝑋1,𝑋𝑋2,𝑋𝑋3,𝑋𝑋5,𝑋𝑋7,𝑋𝑋10) and the treatment assignment: 
Continuous Outcome: Generating Model 
𝑆𝑆(𝑌𝑌) = 1.5 + 𝐴𝐴 ∗ 𝜃𝜃(𝑿𝑿) + 0.28𝑋𝑋1 − 0.20 𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋2) + 0.15𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋3) + 0.14𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋5)+ 0.09𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋7) + 0.22𝑋𝑋10 
Binary Outcome: Generating Model 
𝑖𝑖𝑜𝑜𝑙𝑙𝑖𝑖𝑖𝑖(𝑌𝑌) = 𝑖𝑖𝑜𝑜𝑙𝑙𝑖𝑖𝑖𝑖(0.30) + 𝐴𝐴 ∗ 𝜃𝜃(𝑿𝑿) + 0.80𝑋𝑋1 − 0.50 𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋2) + 0.40𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋3) + 0.20𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋5)+ 0.20𝑠𝑠𝑖𝑖𝑜𝑜(𝑋𝑋7) + 0.30𝑋𝑋10 
where std(.) is a standardization function and 𝜃𝜃(𝑿𝑿) depends on one of two treatment related 
scenarios: (1) Null setting where there was no treatment difference for all patients, 𝜃𝜃(𝑿𝑿)  = 0, 
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(2) Subgroup setting where 𝜃𝜃(𝑿𝑿)  varies and there are four distinct subgroups. In the Subgroup 
setting, while the overall treatment effect is 0.237 (continuous) or 0.11 (binary), 30% of the 
patients receive no benefit from the study drug. Subgroups were defined by (𝑋𝑋1,𝑋𝑋2,𝑋𝑋3).  See 
below table for more details. Lastly, we note that the simulation values were chosen such that an 
unadjusted linear/logistic regression would yield ~90% power in testing the overall treatment 
effect in the Subgroup settings. 
Supplementary Table 1: Simulation Treatment Effects by Subgroup and Setting (Continuous) 
   Treatment Effect 
Subgroup Prevalence 
(%) 
E(Y) Null Scenario Subgroup Scenario 
𝑋𝑋1 = 1,𝑋𝑋2 < −0.20,𝑋𝑋3 > 0.47 2 2.32 0 0.40 
𝑋𝑋1 = 1,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 > 0.47 5 2.04 0 0.40 
𝑋𝑋1 = 1,𝑋𝑋2 < −0.20,𝑋𝑋3 ≤ 0.47 5 2.02 0 0.40 
𝑋𝑋1 = 0,𝑋𝑋2 < −0.20,𝑋𝑋3 > 0.47 10 1.96 0 0.40 
𝑋𝑋1 = 1,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 ≤ 0.47 8 1.76 0 0.33 
𝑋𝑋1 = 0,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 > 0.47 15 1.68 0 0.33 
𝑋𝑋1 = 0,𝑋𝑋2 < −0.20,𝑋𝑋3 ≤ 0.47 25 1.65 0 0.30 
𝑋𝑋1 = 0,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 ≤ 0.47 30 1.38 0 0 
Overall 100 1.66 0 0.237 
 
Supplementary Table 2: Simulation Treatment Effects by Subgroup and Setting (Binary) 
 
   Treatment Effect 
Subgroup Prevalence 
(%) 
E(Y) Null Scenario Subgroup Scenario 
𝑋𝑋1 = 1,𝑋𝑋2 < −0.20,𝑋𝑋3 > 0.47 2 0.38 0 0.25 
𝑋𝑋1 = 1,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 > 0.47 5 0.40 0 0.25 
𝑋𝑋1 = 1,𝑋𝑋2 < −0.20,𝑋𝑋3 ≤ 0.47 5 0.35 0 0.25 
𝑋𝑋1 = 0,𝑋𝑋2 < −0.20,𝑋𝑋3 > 0.47 10 0.35 0 0.25 
𝑋𝑋1 = 1,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 ≤ 0.47 8 0.37 0 0.17 
𝑋𝑋1 = 0,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 > 0.47 15 0.36 0 0.17 
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𝑋𝑋1 = 0,𝑋𝑋2 < −0.20,𝑋𝑋3 ≤ 0.47 25 0.32 0 0.11 
𝑋𝑋1 = 0,𝑋𝑋2 ≥ −0.20,𝑋𝑋3 ≤ 0.47 30 0.33 0 0 
Overall 100 0.34 0 0.11 
 
For each method with 𝑘𝑘 = 1, …𝐾𝐾 subgroups identified in each simulation, the following 
metrics were then calculated: 
𝑀𝑀𝑖𝑖𝑎𝑎𝑠𝑠(𝑀𝑀𝑂𝑂𝑖𝑖𝑖𝑖𝑎𝑎𝑖𝑖𝑖𝑖) = � 𝑛𝑛𝑘𝑘(
𝑘𝑘
𝜃𝜃�𝑘𝑘 −  𝜃𝜃𝑘𝑘)/� 𝑛𝑛𝑘𝑘
𝑘𝑘
 
𝑀𝑀𝑖𝑖𝑎𝑎𝑠𝑠(𝐴𝐴𝑢𝑢𝑠𝑠) = � 𝑛𝑛𝑘𝑘|
𝑘𝑘
𝜃𝜃�𝑘𝑘 −  𝜃𝜃𝑘𝑘|/� 𝑛𝑛𝑘𝑘
𝑘𝑘
 
𝑀𝑀𝑆𝑆𝑆𝑆 = � 𝑛𝑛𝑘𝑘�𝜃𝜃�𝑘𝑘 −  𝜃𝜃𝑘𝑘�2
𝑘𝑘
/� 𝑛𝑛𝑘𝑘
𝑘𝑘
 
𝐶𝐶𝑜𝑜𝑂𝑂𝑖𝑖𝑖𝑖𝑎𝑎𝑙𝑙𝑖𝑖 = � 𝑛𝑛𝑘𝑘𝐶𝐶�𝜃𝜃𝑘𝑘 ∈ 𝐶𝐶𝐶𝐶0.95(𝜃𝜃�𝑘𝑘)�
𝑘𝑘
/� 𝑛𝑛𝑘𝑘
𝑘𝑘
 
where 𝜃𝜃𝑘𝑘 is the true treatment effect based on subgroup-specific rules and is estimated using 
10,000 simulation patients (not just the N=800 simulated data-set). Note that each metric is 
weighted by the subgroup-specific sample size. While Bias(Overall) should be roughly zero, it 
can be misleading as subgroups with large positive bias can be offset by subgroups with large 
negative bias. Bias(Abs) avoids this issue. 𝐶𝐶�𝜃𝜃𝑘𝑘 ∈ 𝐶𝐶𝐶𝐶0.95(𝜃𝜃�𝑘𝑘)� is an indicator for whether the 
95% two-sided CI contains the true treatment effect. Filtering and the subgroup model were also 
assessed by counting up how many of the predictive and prognostic, and noise variables were 
included in the subgroup rule definitions. Ideally, the subgroup definitions would always include 
the true predictive covariates, (𝑋𝑋1,𝑋𝑋2,𝑋𝑋3). All metrics were averaged across 1000 simulations for 
each scenario.   
